Pangen Biotech
팬젠 · 222110
Health Care Pharmaceuticals · KOSDAQ
Market cap US$48M (₩66.3B)
Overview
Pangen Biotech makes a biosimilar version of erythropoietin (EPO), a medicine that treats anemia in patients with chronic kidney disease, and supplies it to healthcare markets in South Korea, Malaysia, the Philippines, Saudi Arabia, and Thailand.
Hospitals and healthcare providers are the end users of its EPO products, which are approved and marketed under the brand names Erysaa and Panpotin in those countries. Listed on KOSDAQ, South Korea's tech and small-cap board, the company also runs a contract development and manufacturing (CDMO) business, producing biopharmaceuticals on behalf of other drug developers. Its proprietary cell-line and protein-expression technology, called PanGen CHO-TECH™, underpins both its own product pipeline and its CDMO services.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$5.3M
- FY2024US$10.6M
- FY2025US$9.7M
Operating profit
- FY2023−US$3.1M
- FY2024US$739.3K
- FY2025US$1.1M
Net income
- FY2023−US$3.3M
- FY2024US$683.8K
- FY2025US$1.5M
Key ratios (FY2025)
Why it matters
The company's proprietary PanGen CHO-TECH™ platform, a specialized protein-expression technology built on CHO cells, is the in-house capability that supports both its biosimilar products and its contract manufacturing business.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?